MOTS-c / 5-Amino-1MQ
A combined metabolic-research preparation pairing a mitochondrial-derived peptide with a small-molecule NNMT inhibitor.
Molecular Profile
- Type
- Peptide / small-molecule blend
Components
MOTS-c
- Molecular formula
- C101H152N28O22S2
- Molecular weight
- ~2,175 g/mol
- CAS number
- 1627580-64-6
- Sequence
- MRWQEMGYIFYPRKLR
5-Amino-1MQ
- Molecular formula
- C10H11IN2
- Molecular weight
- 286.11 g/mol
- CAS number
- 42464-96-0
Mechanism & Target Class
Combines a mitochondrial-derived peptide (MOTS-c) with a small-molecule enzyme inhibitor (5-Amino-1MQ) that act on separate metabolic pathways; no single target applies. MOTS-c is a short cationic peptide encoded by an open reading frame within mitochondrial 12S rRNA (MT-RNR1 locus); mechanistic studies link it to inhibition of the folate-methionine one-carbon cycle, AICAR accumulation, and AMP-activated protein kinase (AMPK) activation, with stress-responsive nuclear translocation. 5-Amino-1MQ is a substrate-site small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT; EC 2.1.1.1), the cytosolic enzyme that transfers a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide, yielding 1-methylnicotinamide (1-MNA) and S-adenosyl-L-homocysteine; the cationic quinolinium ring occupies the nicotinamide substrate-binding pocket.
Storage & Handling
- Lyophilized
- -20°C; components typically stable ~24 months desiccated and protected from light.
- Handling
- Avoid freeze-thaw; aliquot; protect from light and moisture. The peptide component carries oxidation-sensitive methionine residues; the small-molecule salt is hygroscopic — keep desiccated.
References (23)
Reviews
1Wan W, et al. (2023). J Transl Med
- 2
Yoon TK, et al. (2022). Diabetes Metab J
- 3
Miller B, et al. (2022). J Clin Invest
- 4
Frontiers in Pharmacology (2024 review) (2024). Frontiers in Pharmacology
- 5
Roberti A, Fernández AF, Fraga MF. (2021). Mol Metab
- 6
Pissios P. (2017). Trends in Endocrinology & Metabolism
Clinical
7Reynolds JC, et al. (2021). Sci Rep
- 8
Qin Q, et al. (2018). Int J Cardiol
Primary research
9Kim SJ, et al. (2024). iScience
- 10
Kumagai H, et al. (2021). Am J Physiol Endocrinol Metab
- 11
Reynolds JC, et al. (2021). Nat Commun
- 12
D'Souza RF, et al. (2020). Aging (Albany NY)
- 13
Lu H, et al. (2019). J Mol Med
- 14
Kim KH, et al. (2018). Cell Metabolism
- 15
Lee C, et al. (2015). Cell Metabolism
- 16
Babula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H. (2024). Diabetes, Obesity and Metabolism
- 17
Dimet-Wiley AL, et al. (2024). Scientific Reports
- 18
Awosemo O, Neelakantan H, Watowich S, Ma J, Wu L, Chow DS, Liang D. (2021). Journal of Pharmaceutical and Biomedical Analysis
- 19
Sampson CM, Dimet AL, Neelakantan H, Ogunseye KO, Stevenson HL, Hommel JD, Watowich SJ. (2021). Scientific Reports
- 20
Neelakantan H, Brightwell CR, Graber TG, Maroto R, Wang HYL, McHardy SF, Papaconstantinou J, Fry CS, Watowich SJ. (2019). Biochemical Pharmacology
- 21
Neelakantan H, et al. (2018). Biochemical Pharmacology
- 22
Neelakantan H, Wang HY, Vance V, Hommel JD, McHardy SF, Watowich SJ. (2017). Journal of Medicinal Chemistry
- 23
Kraus D, Yang Q, Kong D, et al. (2014). Nature
